Holen Sie sich die Stockscreener-App
14.77
0.47%
-0.07
Schlusskurs vom Vortag:
$14.84
Offen:
$15.24
24-Stunden-Volumen:
6.50M
Relative Volume:
1.57
Marktkapitalisierung:
$11.46B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-1.08B
KGV:
-10.22
EPS:
-1.4448
Netto-Cashflow:
$-326.53M
1W Leistung:
-15.79%
1M Leistung:
-15.79%
6M Leistung:
-19.33%
1J Leistung:
-25.14%
1-Tages-Spanne:
$14.65
$15.35
1-Wochen-Bereich:
$14.17
$16.84
52-Wochen-Spanne:
$13.83
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
14.77 | 11.52B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
5 Best Large Cap Stocks Under $30 With Highest Upside Potential - Insider Monkey
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data - Insider Monkey
Summit falls despite Phase 3 ivonescimab data in NSCLC - MSN
Insider Buying: Manmeet Soni Acquires 50,000 Shares of Summit Th - GuruFocus
Summit Therapeutics COO & CFO Soni buys $722,250 in stock By Investing.com - Investing.com South Africa
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stock By Investing.com - Investing.com South Africa
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stock - Investing.com UK
Summit Therapeutics (SMMT) Co‑CEO associated trust purchases 100,000 shares at $14.60 - Stock Titan
Summit Therapeutics (SMMT) co-CEO buys 100K shares via revocable trust - Stock Titan
Summit Therapeutics Insider Bought Shares Worth $722,250, According to a Recent SEC Filing - marketscreener.com
Summit Therapeutics COO, CFO Purchased Shares Worth Over $722K - TradingView
Summit Therapeutics COO & CFO Soni buys $722,250 in stock - Investing.com
Executive Manmeet Singh Soni buys 50K Summit Therapeutics (SMMT) shares - Stock Titan
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference - Yahoo Finance
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy - Yahoo Finance
Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC - Insider Monkey
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology CongressSlideshow (NASDAQ:SMMT) 2026-06-03 - Seeking Alpha
Summit Therapeutics Enables Affiliate and Insider Share Purchases - TipRanks
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics directors, executives likely to buy shares under ATM program - TradingView
Summit Therapeutics (SMMT) leaders may buy shares via existing ATM - Stock Titan
Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus - Gotrade
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT) - The Globe and Mail
Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments - Insider Monkey
Summit Therapeutics (SMMT) Sheds 10.4%, This Analyst is Pessimistic - Insider Monkey
Summit Therapeutics (SMMT) Shares Drop Despite Positive Cancer T - GuruFocus
Exclusive BAC Article: Akeso And Summit: Positive China HARMONi-6 Trial Ivonescimab Squamous NSCLC, HARMONi-3 Data From Summit 2nd Half 2026 & 1st Half 2027, And Catalysts (OTCMKTS:AKESF) - Seeking Alpha
Summit Therapeutics (SMMT) Slides As Bearish Calls Mount - StocksToTrade
Summit Therapeutics Inc. (SMMT) once dropped over 12.8%, approaching the May 1st low of $15.14. - Bitget
Summit Therapeutics Reports Promising Phase II Ivonescimab Results in Metastatic Colorectal Cancer at ASCO 2026 - Minichart
Summit Therapeutics slides as traders digest ASCO ivonescimab update - Quiver Quantitative
Summit Therapeutics (SMMT) Revenue BreakdownMain Composition - Moomoo
What's Going On With Summit Therapeutics Stock On Monday? - Benzinga
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $7.7 to $40 - Moomoo
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet - Yahoo Finance
Bernstein reiterates Summit Therapeutics stock Underperform on trial concerns By Investing.com - Investing.com Canada
Summit Therapeutics stock maintained at Overweight by Cantor on positive trial data - Investing.com Canada
Stifel reiterates Summit Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Summit drops as concerns over older patients cloud cancer trial data - marketscreener.com
Summit Therapeutics Reports Strong Interim Ivonescimab Phase II Data - TipRanks
Summit Therapeutics (SMMT) posts positive ASCO 2026 ivonescimab survival and response data - Stock Titan
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - marketscreener.com
Summit Therapeutics Inc. (SMMT) Stock Analysis: A Potential 62.66% Upside In Biotech Innovation - DirectorsTalk Interviews
SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor - Yahoo Finance
Summit Therapeutics (SMMT) Unveils Promising Results from Colore - GuruFocus
Summit Therapeutics (SMMT) to Present Phase III Trial Results at ASCO 2026 - GuruFocus
13 Best Short Squeeze Stocks to Invest In - Insider Monkey
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
1.13%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):